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Abstract 
Purpose: To develop suitable solid lipid nanoparticles (SLN) containing carvedilol (CL) for controlled 
delivery to site of action.  
Methods: Solid lipid nanoparticles (SLNs) containing carvedilol (CL) were prepared by hot 
homogenization and ultrasonication methods. The SLNs were characterized in terms of entrapment 
efficiency, particle size, zeta potential, polydispersity index, cytotoxicity, solid state characterization and 
drug release. The stability of the formulations was investigated by monitoring their properties for a 
period of 3 months. 
Results:  The mean size of the nanoparticles was in the range of 130.70 ± 1.80 to 154.40 ± 2.40 nm. 
Solid state analysis showed that carvedilol was uniformly dispersed in the lipid nanoparticles. Drug 
entrapment efficiency ranged from 96.03 ± 0.13 to 93.46 ± 0.21 % while in vitro cumulative drug release 
from the nanoparticles in simulated intestinal fluid (SIF) and phosphate buffer containing 30% PEG (pH 
6.8) was 96.57 ± 0.40 and 75.13 ± 0.15 %, respectively, at the end of 24 h. In vitro release of carvedilol 
from SLNs followed fist order kinetics and Higuchi diffusion model. 
Conclusion: The SLNs developed in this study represent a promising safe system for the sustained 
and controlled delivery of carvedilol.  
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Cardiovascular diseases cause a significant 
number of deaths around the world. Considering 
the number of patients worldwide who 
experience cardiovascular problems, concerted 
efforts have been made to develop drugs to 
prevent and/ or treat cardiovascular diseases. 
Consequently, there are now several drugs that 
are available in the market, including carvedilol 




phenoxy)ethyl)amino)-2-propanol, is a non-
selective β-blocking agent with vasodilating 
action due primarily to its blockage of α1 –
receptors. This makes it usefull for the treatment 
of hypertension and angina pectoris [2,3]. 
However, preliminary data suggest that it is a 
strong β-adrenergic antagonist but a weak 
vasodilator [4]. 
 
Although CL is well absorbed in the 
gastrointestinal tract, it is extensively 
metabolized in the liver leading to decreased 
bioavailability of about 25 % [5]. The oral 
bioavailability remains low because of significant 
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first-pass hepatic metabolism by cytochrome 
P450 and also because of its short plasma half-
life [6]. Long-term therapy of cardiovascular 
diseases by orally administered CL may result in 
poor patient compliance because of low 
bioavailability. 
 
Lipid particles are of great importance to drug 
researchers and developers because of their 
ability to avoid hepatic first pass metabolism and 
because they enhance intestinal permeability 
[6,7]. 
 
Various controlled delivery systems have been 
developed from lipids and introduced with the 
aim of improving solubility, stability and 
bioavailability of poorly absorbed drugs [8]. Solid 
lipid nanoparticles (SLNs) have received 
increased research interest in recent years due 
to their superior characteristics and advantages 
over biopolymer-based colloidal nanoparticles 
[9]. Solid lipid nanoparticles are evaluated as 
alternative drug delivery system in order to 
bypass the first pass metabolism [10]. As a way 
of improving the bioavailability of orally 
administered CL, drug-loaded solid lipid 
nanoparticles were developed using trimyristin as 
lipid and polyethylene glycol sorbitan monooleate 
as surfactant. It has also been shown to be non-
toxic for human use and officially recognized as a 
pharmaceutical excipient [5]. In this study, 
carvedilol-loaded SLNs were prepared using hot 







Carvedilol was a kind gift from Santa-Farma 
(İstanbul, Turkey). Dynasan 114 (glyceryl 
trimyristate) was purchased from Condea 
(Witten, Germany), and Tween 80 
(polyoxyethylene-80 sorbitan monooleate) from 
Merck (Hohenbrunn, Germany). Purified water 
(MilliQ, Millipore,USA) was used whenever water 
was required throughout the study. All other 
chemicals were of analytical grade. 
 
Preparation of carvedilol loaded solid lipid 
nanoparticles 
 
SLNs were prepared by hot homogenization 
followed by ultrasonication method based on the 
formula given in Table 1. Lipid (5 %) was melted 
at about 75 ºC (10 ºC above melting point of the 
lipid) and the drug (carvedilol, 5 % relative to 
lipid) was added to obtain a clear melted 
solution. An aqueous phase was prepared by 
dissolving surfactant (Tween 80, 2 - 5 %) in 10 
ml double-distilled water and heated to same 
temperature of the oil phase. The hot aqueous 
phase was added to the oil phase and 
homogenization was carried out at a pestle 
speed of 8000 rpm at a temperature 75 ºC, using 
Ultra Turrax® T 25 basic homogenizer (IKA, 
Staufen, Germany) for 5 min. Hot oil in water 
emulsion was obtained and the mixture was 
sonicated for 5 min at 60 % power using a 
sonicator (Sonics, USA). Carvedilol loaded SLNs 
were obtained by allowing hot nanoemulsion to 
cool to room temperature. Thermal stability of 
carvedilol was not evaluated because published 
reports attest to the thermal stability of carvedilol 
[11].  
 


















F1 0.05 0.5 0.2 9.25 
F2 0.05 0.5 0.3 9.15 
F3 0.05 0.5 0.4 9.05 
F4 0.05 0.5 0.5 8.95 
Placebo - 0.5 0.4 9.10 
 
Evaluation of particle size and zeta potential 
 
Mean diameter of the bulk population and the 
particle distribution via the polydispersity index 
(PI) and zeta potential of SLNs were analyzed by 
a Zetasizer Nano ZS (Malvern Instruments, UK). 
Distilled water with a conductivity value of 50 
μS/cm was adjusted using sodium chloride (0.1 
N) at pH 7.4 and used in zeta potential analyses. 
Electrostatic mobility was converted to zeta 
potential using Helmholtz-Smoluchowski 
equation. For the analyses, constant volume  (20 
μL) of formulations were dispersed in 1 mL of 
distilled water and particle size (PI) and zeta 
potential were recorded (n=3). 
 
Scanning electron microscopy  
 
The morphology of placebo and CL-loaded SLNs 
were determined with a scanning electron 
microscopy using Carl Zeiss Microscopy 
(SUPRA 50VP model, Oberkochen, Germany) 
instrument. Solid lipid nanoparticles were 
deposited on metallic stubs placed in liquid 
nitrogen and dried under vacuum. Then sputter 





Differential scanning calorimetric curve of pure 
carvedilol, polymer and mixture of drug and 
polymer measurement were carried out by using 
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Shimadzu (DSC-60, Shimadzu, Japan) 
instrument equipped with a liquid nitrogen sub-
ambient accessory. The samples ( 2-6mg) were 
accurately weighed in aluminium pans 
hermetically sealed and heated at a rate of 10 ºC 
per min in a 30 to 250 ºC temperature range, 
under nitrogen flow of 50 mL min−1. 
Temperature-dependent structure and 
crystallinity changes in the lipids were analysed. 
 
Characteristics of the solid lipid structures of 
SLNs as well as stability changes in CL after the 
preparation of the formulation was also analysed 
using powdered X-ray diffractometry (PXRD), 
product of Rigaku, Tokyo, Japan. The data were 
recorded over the 2θ range from 3° to 45° at a 
scan rate of 0.04°. 
 
In order to examine the lipid matrix of the 
improved SLNs dispersion relative to the pure 
drug and pure solid lipid, 1H- NMR techniques 
were used to examine the possible effect of CL 
on the crystallization process. High-resolution 
proton nuclear magnetic resonance (1H-NMR) 
spectra of samples prepared, were obtained on 
an NMR instrument (Ultra Shield CP MAS, 
Germany) operating at 500 MHz and 20°C. NMR 
analysis (1H-NMR) of the solution was performed 
after dissolving the materials in deutero 
chloroform (CDCl3). 
 
Interaction of drug with the lipid was determined 
by FT-IR Spectroscopy (Shimadzu IR-Prestige-
21, Japan). The pellets were produced by mixing 
1 mg of sample with 200 mg potassium bromide 
at high compression pressure. The scan range 
selected was 400 to 4000 cm -1 and the 
revolution was selected was 4 cm -1. The pellets 
were examined and the spectra were compared 
between pure drug, lipid and the formulations 
[13]. 
 
Assessment of entrapment efficiency  
 
The entrapment efficiency (EE) of carvedilol-
loaded SLNs was determined by measuring the 
concentration of drug encapsulated within and 
adsorbed onto the nanoparticles. About 1 ml of 
CL-SLNs dispersion was diluted using 5 mL of 
phosphate buffer (pH 6.8) containing 30 % PEG 
400 and centrifuged at 11,000 rpm (Eppendorf 
Centrifuge 5417R, Germany) for 15 min. The 
amount of free drug in the supernatant was 
estimated by using HPLC at wavelength of 242 
nm, and EE was calculated using Eq 1. 
 
EE (%) = {(WA - Wb)/WA}100 ................... (1) 
 
where WA is the amount of initial drug used for 
the assay, and Wb is the amount of free drug in 
the supernatant after centrifugation of the 
aqueous dispersion [14]. 
 
Stability studies  
 
Formulations were stored in amber bottles at 
different temperatures and relative humidity. The 
effects of duration of storage and storage 
condition on entrapment efficiency were 
calculated. Stability studies revealed the physical 
stability of these lipid particles after 3 months of 
storage at different temperatures. The SLNs 
were evaluated for particle size, zeta potential 
value, PDI and EE on 30th, 60th and 90th days. 
 
In vitro drug release studies 
 
In vitro drug release of CL from optimized SLN 
formulations were studied through dialysis bag 
(cellulose membrane) which was sealed with 
clamps and stirred at 50 rpm using magnetic 
stirrer. The temperature was maintained at 37 ± 
0.5°C under sink conditions. The dispersion was 
transferred into dialysis membrane which was 
previously soaked in double distilled water for 12 
hours, tied properly at both the ends and kept 
inside the glass. The ın vitro release studies 
were conducted both in simulated intestinal fluid 
(SIF) and phosphate buffer (pH 6.8) containing 
30 % PEG 400.  
 
The dialysis medium (50 mL) was stirred at 100 
rpm over a magnetic stirrer maintained at 37 ± 1 
ᵒC. At pre-determined time intervals, 1-mL 
samples were withdrawn from the dissolution 
media respectively and analyzed for the drug 
content using HPLC (Shimadzu Corporation, 
Kyoto, Japan) at 242 nm and fresh 1 mL, of each 
medium was added to the appropriate system. 
By determining the amount of CL released at 
various time intervals, the % release versus time 
graphs were plotted for the formulations. 
 
The drug content of each formulation was 
determined by HPLC (Shimadzu Corporation, 
Kyoto, Japan). The mobile phase was a mixture 
of 0.03M potassium dihydrogen phosphate (pH 
3.0) buffer: acetonitrile: methanol (60:50:10, 
v:v:v:), prepared daily and de-gassed by 
sonication and filtered through 0.45 μm 
membrane filter before the experiment. The flow 
rate was set at 1.0 mL/min resulting in a run time 
of 10 min per sample. The injection volume was 
20 μL. Detection was performed at 242 nm and 
samples were analyzed at room temperature 
[15]. In order to study the mechanism of drug 
release from the SLNs, the release data were 
fitted to different equations with DDSolver 
programme [16]. 
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Evaluation of cytotoxicity 
 
Colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) method was 
used for the quantitative determination of 
cytotoxicity of the formulations on 3T3 mouse 
embryo fibroblast cell lines. The cells (2 × 104) 
were seeded in a 96-well plate (Greiner, Sigma-
Aldrich, Germany), with RPMI 1640 (Sigma 
Aldrich, Germany) medium. The RPMI 1640 
medium was supplemented with 10 % FBS and 1 
% antibiotics (penicillin/streptomycin). The cells 
were incubated at 37 °C for 24h in a humidified 
atmosphere containing 5 % CO2. 
 
At the end of the 24-hour incubation, the 
formulations, with the cell culture medium were 
added to the cells at the rates determined. The 
cells were left for 24 and 48 hours of incubation. 
At the end of the 24 and 48 h incubation periods, 
the formulations were withdrawn from the wells 
and 20 μL of MTT dye (Greiner, Sigma-Aldrich, 
diluted with PBS to 5 mg/mL concentration) 
solution was added. The plates were incubated 
for 4 h under the same conditions earlier 
mentioned. Thereafter, 200 μL 
spectrophotometric DMSO was added to each 
well to dissolve the resultant formazan crystals. 
After 30 min of incubation, absorbance of the 
content of each plate was measured at 570 nm 
using a multi-mode microplate reader (Cytation 




Each experiment was carried out three 
independent times and the data are presented as 
mean ± SEM (standard error of mean). Statistical 
analysis of the data were carried out using SPSS 
software, version 11.5. Differences were 
considered statistically significant when the P-




Physicochemical characteristics of SLNs 
 
The results of the particle size and other 
characteristics of the formulations analysed are 
presented in Table 2. The particle size of all the 
formulations ranged from 130 to 154 nm; PDI of 
formulations ranged from 0.147 to 0.247, while 
the zeta potential were from −14.7 to −27.7 mV. 
From the results obtained, formulations 
containing 4 % Tween 80 (F3) showed relatively 
lower particle sizes. The optimum formulation 
was selected as F3 because of the smaller 
particle size. 
 











F1 136.7±2.4 -5.6±1.45 0.228±0.032 
F2 135.6±1.7 -4.7±1.06 0.247±0.051 
F3 130.7±1.8 -2.7±1.76 0.197±0.032 
F4 154.4±2.4 -3.9±1.68 0.150±0.129 
Placebo 138.4±1.5 -8.4±1.56 0.147±0.051 
 
Figure 1 shows the images of surface 
morphology of placebo, pure CL, pure lipid and 
optimum CL-SLN formulations. The results 
showed that the particles were flakes with a 
narrow size distribution, and had smooth 
surfaces. Particle size results and SEM images 
pointed out that particles were different not only  
in size, but also  in shape.,  Carvedilol pure 
powders had  a non-uniform shape, while SLN 
formulations had a flaky shape [18,19].  
 
The solid state of CL in formulation was 
measured by differential scanning calorimetry 
(DSC) and powder X-ray diffractometry (PXRD).  
 
 
Figure 1: SEM images of CL (a), Dynasan-114 (b), Placebo (c), F3 (d) 
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As shown in the DSC patterns (Figure 2), pure 
carvedilol showed a pure and clear endothermic 
melting peak at 116.7°C, which is indicative of 
the crystalline. 
 
Characteristics of CL 
 
DSC studies were performed to confirm the 
absence of drug-excipient interactions. The DSC 
study revealed the absence of any chemical 
interaction between CL and lipids. CL 
endothermic peak was not observed in DSC 
thermogram of SLN formulations owing to the 
molecular inclusion of CL in the lipid matrix of 
Dynasan-114. This suggests that CL exists in 
amorphous state in SLNs. After incorporation into 
SLN formulations, the characteristic peak of CL 
disappeared completely. 
 
In order to confirm the physical state of carve-
dilol, PXRD measurement was performed. Figure 
3 shows the PXRD curves of pure carvedilol, 
Dynasan-114 powder, lyophilized CL-SLN.  
 
In Figure 3, pure CL and lipid showed compact 
and characteristic diffraction peaks, respectively. 
However, no sign of the typical crystalline peaks 
of CL was observed for both placebo and SLN 
formulations. The results obtained from DSC and 
PXRD combined, show that carvedilol 
lyophillized formulations were in the amorphous 
state. Numerous diffraction peaks of carvedilol 
were observed at 2θ of 12.4°, 24.4° and 26.1°, 
and this reveals the crystalline nature of 
carvedilol [1,18,19]. 
 
The 1H- NMR measurements of pure Carvedilol, 
Dynasan-114, Placebo and Cl-SLN were as seen 
in Figure 4 [19]. 
 
Analysis of the FTIR spectra as seen in Figure 5 
revealed absorption bands at 3345 cm-1 
corresponding to the stretching of the NH and 
OH peaks merged together. İn addition, CL 
samples showed bands at 2924 cm-1, related to 
C-H stretching, and at 1598 cm-1, related to the 
bending vibrations of the NH group. A few 
characteristic peaks of CL were seen in both CL-
SLN FT-IR patterns. Compared to pure lipids, 
and placebo formulation, FT-IR peaks of F3 CL-
SLN were less intense. 
 
Entrapment efficiency and stability  
 
Entrapment efficiency is an important parameter 
for characterizing the SLN formulations. F3 
formulation was analyzed for entrapment 
efficiency by HPLC, and the results are shown in 
Table 3. From the results obtained, the 
formulation showed good entrapment efficiency 
of 96.03 ± 0.13 %. 
 
Stability studies were conducted for optimized 
formulation (F3) which showed better size, better 
PDI, better zeta potential, and better EE. 
 
The kinetic models used were zero-order, first-




   Figure 2: DSC profiles of; CL (a), Dynasan-114 (b), Placebo (c), F3 (d) 
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Figure 3: PXRD patterns of; CL (a), Dynasan-114 (b), 
placebo (c), F3 (d) 
 
In vitro drug release 
 
The results from studies on release of carvedilol 
from SLN optimum formulations (F3) both in 
simulated intestinal fluid (SIF) and in phosphate 
buffer + 30 % PEG 400 showed that there was 
controlled release of drug from the solid lipid 
nanoparticles. An amount of 75.13 ± 0.15 % of 
carvedilol was released in SIF in 24 h, while 
96.57 ± 40 % of carvedilol was released in 
phosphate buffer + 30 % PEG 400 in 24 h. When 
compared, the cumulative release in pH 6.8 
phosphate buffer was more than that of SIF. 
 
In order to study the mechanism of drug release 
from solid lipid nanoparticles and release of pure 
drug, the release data were fitted to different 
equations with DDSolver programme and the 




Figure 4. Proton nuclear magnetic resonance 
spectroscopy (1H- NMR) spectra of CL (a), Dynasan-
114 (b), placebo (c), F3 (d) 
 
In vitro cytotoxicity 
 
The results obtained from SLN and carvedilol 
application to fibroblast cells after 24 and 48 
hours are presented in Figure 7. 
 
Based on the 24 h cytotoxicity test results (Figure 
7(A), Dynasan showed cell viability over 50 % 
(59.50 ± 1.54 %) even at the highest doses. CL 
and CL-loaded solid lipid nanoparticles begun to 
show high cytotoxicity after 25 µg/mL, with IC50 
values of 41.3 ± 2.30 and 38.5 ± 1.32 µg/mL, 
respectively). 
Kipriye et al 





Figure 5: Infrared absorption spectra of CL (a), Dynasan-114 (b), placebo (c), and F3 (d) 
 
Table 3: Stability results of optimized (F3) CL-SLN formulation (ZP: Zeta potential) 
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Figure 6: In vitro drug release profiles: CL-SLN (F3) in SIF (▪); CL-SLN (F3) in SIF + pH 6.8 + 30 % PEG (▫); pure 
CL in SIF (●); pure CL in SIF + pH 6.8 + 30 % PEG (◦) 
 
Table 4: Release kinetics of CL- SLN (F3) and pure CL (*AIC: Akaike information criterion) 
 
Formulation First order  Higuchi  
k1 R AIC kH r AIC 
Pure CL 
(pH 6.8 + 30 
% PEG) 
1.172 0.697 76.495 51.844 0.830 71.306 
Pure CL 
(SIF) 0.664 0.520 89.432 36.337 0.680 85.374 
CL-SLN  
(SIF) 0.137 0.583 116.744 22.352 0.547 117.797 
CL-SLN 
(pH 6.8 + 30 
% PEG) 
0.294 0.820 110.759 27.218 0.622 120.399 
 
From the 48 h cytotoxicity test results [(Figure 
7(B)], it was shown that the formulations showed 
cytotoxicity. The IC50 values for CL and C- 
loaded SLN formulations were 25.68 ± 3.33 
µg/mL and 15.48 ± 1.85 µg/mL, respectively, but 




Carvedilol-encapsulated SLNs were successfully 
developed using hot homogenization and 
ultrasonication methods according to the 
formulae given in Table 1 [20]. The mean particle 
size of formulations ranged from 130.7 ± 1.8 to 
154.4 ± 2.4 nm with low polydispersity indices 
indicating narrow particle size distribution 
(Table2). It was also clear that increasing the 
concentration of the surfactant from 1 to 4 % 
(w/v) resulted in a significant decrease in the 
particle size [21].The mean diameter of the 
particles make them  suitable for  gastrointestinal 
absorption by M-cells on Peyer’s patches [22]. 
The PDI used as a measure of a unimodal size 
distribution was within the acceptable limits for all 
the formulations. Usually, a small value of PDI 
indicates a homogenous population, while a 
larger PDI means a high heterogeneity in particle 
size [21]. Pure carvedilol had an irregular shape, 
while the lipid Dynasan shape was cluster-like, 
and the CL-SLN (F3) exhibited a flaky shape 
[18]. 
 
Pure CL shows a single sharp endothermic 
melting peak at 116.5 °C, indicating the 
crystalline characteristics of carvedilol. 
 
Kipriye et al 
Trop J Pharm Res, September 2017; 16(9): 2065  
 
 
Figure 7: Cytotoxicity profiles of carvedilol loaded solid lipid nanoparticles incubated for A) 24 h and B) 48 h, via 
MTT assay 
 
This peak was not evident in the thermograms of 
the SLN formulations indicating that CL was not 
in the crystalline state, but rather present in 
amorphous state with the drug completely 
entrapped within the solid lipid [6]. 
 
In order to find out the physical state of CL in the 
formulations, the XRD analyses were performed. 
The diffraction pattern of CL showed that it is 
highly crystalline in nature as indicated by its 
infinite typical peaks with the major characteristic 
diffraction pattern visible at a diffraction angle. 
The XRD interpretation of CL-SLN (F3) 
formulation showed more amorphous 
characteristics relative to the pure CL. There 
were some sharp peaks also seen, which may be 
due to the presence of solid lipid in the 
formulation. The lost peaks of CL in F3 
formulation may be due to incorporation of CL 
between parts of crystal lattice of the lipid, 
leading to changes in the crystallinity of CL 
[17,19,20]. 
 
In order to characterize the integration of CL with 
lipid, 1H- NMR measurements were also carried 
out. A pattern of spin diffusion between protons 
of the solid lipid and protons of the CL has been 
observed [23]. This is in harmony with the finding 
in this study, and clearly indicates that CL was 
incorporated into solid lipid.  Simple 1H-NMR 
spectroscopy permits an easy and rapid 
detection of supercooled melts due to the low 
line widths of the lipid protons. It also allows for 
the characterization of liquid nanocompartments 
in recently developed lipid particles, which are 
made from blends of solid and liquid lipids [19]. 
1H- NMR investigations were used to obtain 
information about the mobility and structure of 
both the nanoparticle system and the 
incorporated drug. The spectrum of the drug-free 
SLN dispersion confirmed the assumption of 
immobilized molecules of the dispersed lipid 
phase. The spectrum was dominated by the 
signals of the emulsifier, Tween, and the huge 
water signal. These results excluded formation of 
supercooled melts of the colloidal dispersed lipid 
after the production process. Comparing the 
drug-loaded SLN formulations with the drug-free 
SLN, there is an essential difference in the 
spectrum peaks and sharpness which could be 
observed due to the integration of Carvedilol 
[1,20,22]. 
 
The typical Fourier transform-infrared (FTIR) 
spectrum pattern of the CL was in the range of 
400 to 4,000 cm−1. The IR spectrum of pure 
carvedilol showed a peak at 3,344.88 cm–1 (N-H, 
str), which corresponds to N-H stretching. The 
hetero-aromatic structure, when present is 
revealed by the occurrence of the C-H stretching 
vibrations which is the characteristic region of 
active agent. These characteristic bonds are 
evident in the CL-SLN (F3) formulations. The 
bands are sharp but of weak-to-minimum 
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intensity. Infrared spectroscopy primarily 
provides information about the interactions 
between different atoms and is very useful for 
displaying information about hydrogen bonds [1]. 
Hydrogen bonding results showing that active 
agent was successfully loaded to particles. 
 
In vitro release studies showed that the release 
of CL from SLN was over 20 hours. The slow 
release of CL is an indication that the active 
agent was at the core and surrounded by the 
lipid. Due to the increased diffusional distance 
the drug would normally have sustained release 
[6,22]. According to highest k and r2 values and 
according to lowest AIC values from DDsolver 
programme, in vitro release of CL from 
formulations followed first order and Higuchi 
models showing the controlled release property 
of formulation. 
 
Among the SLN formulations, F3 was chosen as 
optimum formulation due to its lowest particle 
size and best zeta potential value. The stability 
studies revealed the physical stability of SLN 
after 3 months storage and there was no 
significant change observed in the data. Zeta 
potential is a key Factor used for the evaluation 
of the stability of colloidal dispersions [5,20]. As 
observed from the results F3 formulation was 
negatively charged, indicating a relatively good 
stability and quality. An important parameter with 
respect to SLNs as drug carriers is their capacity 
for drug encapsulation. As mentioned earlier CL 
showed a high entrapment capacity of 96.03 ± 
0.13 % in formulation F3, which after 3 months 
storage, decreased by only 2.68 % to 93.46 ± 
0.21 %. 
 
Cytotoxicity analysis of nanoparticles is vital to 
ensure that it does not present any risk to the 
patient or elicit an acute toxicity response. The 
toxicity of Dynasan nanoparticles of carvedilol 
was studied using 3T3 mouse embryo fibroblast 
cell lines for 24 and 48 h. 
 
In the literature, there is no evidence that 
significant stotoxicity was associated with SLNs 
preparations using Dynasan as a lipid at rates 
ranging from 0.01 % to 10 %. Generally, over 60 
% cell viability was shown [24,25]. 
 
The results obtained in this study also showed a 
reduction of up to 60 % only at the end of the 48-
hour incubation period in formulation prepared 
with Dynasan [25,26]. It was found by the 
inventors that carvedilol caused cytotoxicity on 
different human tumor cell lines depending on 
the dosage and cell-line used. In a study carried 
out by Burman et al [27] carvedilol shows 
significant in vitro cytotoxicity. The ED50 for 
carvedilol was found to be 7 μg / mL on PTC 
(colon) cells whereas 33 μg / mL was found in 
MiaPaCa.2 (pancreas) cells. 
 
Cheng et al [28] showed that carvedilol to be 
non-cytotoxic at concentrations equal to or less 
than 10 µM. Yang et al demonstrated that higher 
dosages (≥ 20 μM) were cytotoxic because at 
such high doses it induced T cell apoptosis, with 
attendant decrease in cell viability [29]. 
 
In this study, carvedilol showed high cytotoxicity 
after 25 µg/mL throughout the 24 h and 48h 
incubation period. When all the results were 
evaluated the formulations showed dose and 
time-dependent toxicities. However, the results 
obtained in this study have similarities and 
differences with the studies of other workers [27-
29] found in literature. The lipid ratio, type and 
amount of the surfactants, the method of 
preparation, the incubation times used in MTT 
and the selected cell type are possible reasons 




The findings of the present study show that 
carvedilol loaded solid lipid nanoparticles were 
prepared successfully by hot homogenization 
and ultrasonication process. The molecular state 
of carvedilol changed from the crystalline state to 
the amorphous state following incorporation into 
solid lipid nanoparticles. The developed 
formulation is stable and safe, and represents a 
promising system for the sustained and 
controlled delivery of carvedilol to target cells, 






This study was supported by Anadolu University 
Scientific Research Foundation (Project no. 
1502S061). 
 
Conflict of Interest 
 
No conflict of interest associated with this work. 
 
Contribution of Authors 
 
The authors declare that this work was done by 
the authors named in this article and all liabilities 
pertaining to claims relating to the content of this 
article will be borne by them.  
Kipriye et al 
Trop J Pharm Res, September 2017; 16(9): 2067  
 
Open Access  
 
This is an Open Access article that uses a fund-
ing model which does not charge readers or their 
institutions for access and distributed under the 
terms of the Creative Commons Attribution 
License (http://creativecommons.org/licenses/by/ 
4.0) and the Budapest Open Access Initiative 
(http://www.budapestopenaccessinitiative.org/rea
d), which permit unrestricted use, distribution, 
and reproduction in any medium, provided the 




1. Alves JM, Prado LD, Rocha HV. Evaluation and 
correlation of the physicochemical properties of 
carvedilol. Pharm Dev Technol. 2016 Nov; 21(7): 856-
866. 
2. Hokama N, Hobara N, Kameya H, Ohshiro S, Sakanashi 
M. Rapid and simple micro-determination of carvedilol in 
rat plasma by high-performance liquid chromatography. 
J Chromatogr B Biomed Sci Appl. 1999; 732(1): 233-
238.  
3. Cátia VD, Cláudia MD, Magdalena LA, Aleksandra W, 
Mariusz RW, Paulo JO. Carvedilol and antioxidant 
proteins in a type I diabetes animal model. Eur J Clin 
Invest. 2017; 47 (1): 19–29. 
4. Li J, Wang L, Wang S, Chen M, Gu E, Hu G, Ge R. 
Simultaneous quantification of carvedilol and its 
metabolites in rat plasma by ultra-performance liquid 
chromatography tandem mass spectrometry and 
pharmacokinetic application. J Chromatogr B Analyt 
Technol Biomed Life Sci. 2015; 1 (974): 138-146. 
5. Aboud HM, El Komy MH, Ali AA, El Menshawe SF, Abd 
Elbary A. Mohammed HE, Adel AA, Shahira FM, Ahmed 
AE. Development, optimization, and evaluation of 
carvedilol-loaded solid lipid nanoparticles for ıntranasal 
drug delivery. AAPS PharmSciTech. 2016; 17 (6): 1353-
1365.  
6. Mishra A, Imam SS, Aqil M, Ahad A, Sultana Y, 
Ameeduzzafar, Ali A. Carvedilol nano lipid carriers: 
formulation, characterization and in-vivo evaluation. 
Drug Deliv. 2016; 23(4): 1486-1494.  
7. O’Driscoll CM, Griffin BT. Biopharmaceutical challenges 
associated with drugs with low aqueous solubility- the 
potential impact of lipid-based formulations. Adv Drug 
Deliv Rev. 2008; 60: 617–624. 
8. Luo Y, Teng Z, Li Y, Wang Q. Solid lipid nanoparticles for 
oral drug delivery: chitosan coating improves stability, 
controlled delivery, mucoadhesion and cellular uptake. 
Carbohydr Polym. 2015; 122: 221-229. 
9. Üner M, Yener G. Importance of solid lipid nanoparticles 
(SLN) in various administration routes and future 
perspectives. International Journal of Nanomedicine. 
2007; 2(3): 289-300. 
10. Venishetty VK, Chede R, Komuravelli R, Adepu L, Sistla 
R, Diwan PV. Design and evaluation of polymer coated 
carvedilol loaded solid lipid nanoparticles to improve the 
oral bioavailability: A novel strategy to avoid 
intraduodenal administration. Colloids Surf B 
Biointerfaces. 2012; 95: 1-9. 
11. Shah MK, Madan P. Elucidation of intestinal absorption 
mechanism of carvedilol-loaded solid lipid nanoparticles 
using Caco-2 cell line as an in-vitro model. Pharm Dev 
Technol. 2014; 29: 1-9. 
12. Jenning V, Thunemann AF, Gohla SH. Characterisation 
of a novel solid lipid nanoparticle carrier system based 
on binary mixtures of liquid and solid lipids. Int J Pharm. 
2000; 199(2): 167-177. 
13. Ranga PM, Jeevitha N. Semi-solid dispersion of 
carvedilol solid lipid nanoparticles for topical delivery, 
EJPMR, 2016; 3(3): 231-238. 
14. Pallavi V, Singh K. Development and evaluation of 
colloidal modified nanolipid carrier: Application to topical 
delivery of tacrolimus. Eur J Pharm Biopharm.2011; 
79(1): 82–94. 
15. Patel LJ, Suhagia BN, Shah PB, Shah RR. RP-HPLC and 
HPTLC methods for the estimation of carvedilol in bulk 
drug and pharmaceutical formulations. Indian J Pharm 
Sci. 2006; 68 (6): 790-793. 
16. Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C, Xie S. 
DDSolver: An Add-In Program for Modeling and 
Comparison of Drug Dissolution Profiles. The AAPS 
Journal. 2010; 12(3): 263-271.  
17. Sharma A, Jain CP, Tanwar YS. Preparation and 
characterization of solid dispersions of carvedilol with 
poloxamer 188. J. Chil. Chem. Soc. 2013; 58(1): 1553-
1557.  
18. Liu D, Pan H, He F, Wang X, Li J, Yang X, Pan W. Effect 
of particle size on oral absorption of carvedilol 
nanosuspensions: in vitro and in vivo evaluation. 
International Journal of Nanomedicine. 2015; 10: 6425–
6434.  
19. Morel S, Terreno E, Ugazio E, Aime S, Gasco MR. NMR 
relaxometric investigations of solid lipid nanoparticles 
(SLN) containing gadolinium(III) complexes, Eur J 
Pharm Biopharm. 1998; 45(2): 157-163. 
20. Mehnert W, Mäder K. Solid lipid nanoparticles 
Production, characterization and applications. Adv Drug 
Deliv Rev. 200; 47(2-3): 165-196. 
21. Zhang L, Han L, Sun X, Gao D, Qin J, Wang J. The use 
of PEGylated liposomes to prolong the circulation 
lifetime of salvianolic acid B. Fitoterapia. 2012; 83(4): 
678-689. 
22. Prasanthi NL, Gondhi S, Manikiran SS, Kumar SN, Rao 
NR. Solid lipid nanoparticles of carvedilol by hot 
homogenization: Formulation and evaluation. 2011; 
2(2): 1-16. 
23. Wissing SA, Müller RH, Manthei L, Mayer C. Structural 
characterization of Q10-loaded solid lipid nanoparticles 
by NMR spectroscopy. Pharm Res. 2004; 21(3): 400-
405. 
24. Olbrich C, Schöler N, Tabatt K, Kayser O, Müller RH. 
Cytotoxicity studies of Dynasan 114 solid lipid 
nanoparticles (SLN) on RAW 264.7 macrophages-
Kipriye et al 
Trop J Pharm Res, September 2017; 16(9): 2068  
 
impact of phagocytosis on viability and cytokine 
production. J Pharm Pharmacol. 2004; 56(7): 883-891. 
25. Schöler N, Hahn H, Müller RH, Liesenfeld O. Effect of 
lipid matrix and size of solid lipid nanoparticles (SLN) on 
the viability and cytokine production of Macrophages. Int 
J Pharm. 2002; 231(2): 167-176. 
26. Rigon RB, Fachinetti N, Severino P, Santana MHA, 
Chorilli M. Skin Delivery and in Vitro Biological 
Evaluation of Trans-Resveratrol-Loaded Solid Lipid 
Nanoparticles for Skin Disorder Therapies. Molecules 
2016; 21: 116.  
27. Burman AC, Mukherjee R, Jaggi M, Singh AT. (2003). 
U.S. Patent No. 6,632,832. Washington, DC: U.S. 
Patent and Trademark Office. 
28. Cheng SM, Yang SP, Ho LJ, Tsao TP, Chang DM, Lai 
JH. Carvedilol Modulates In‐Vitro 
Granulocyte‐Macrophage Colony‐Stimulating 
Factor‐Induced Interleukin‐10 Production in U937 Cells 
and Human Monocytes, Immunol Invest. 2003; 32(1-2): 
43-58. 
29. Yang SP, Ho LJ, Lin YL, Cheng SM, Tsao TP, Chang 
DM, Hsu YL, Shih CY, Juan TY, Lai JH. Carvedilol, a 
new antioxidative b-blocker, blocks in vitro human 
peripheral blood T cell activation by downregulating NF-
kB activity, Cardiovasc Res. 2003; 59(3): 776-787. 
 
